Anastrozole
Rank #447 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$17.4M
Total Cost
626,025
Total Claims
$17.4M
Total Cost
9,765
Prescribers
$28
Cost per Claim
167,381
Beneficiaries
1,447,920
30-Day Fills
$1,784
Avg Cost/Provider
64
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$17.4M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $17.4M total
Top Prescribers of Anastrozole
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Carrie Dul | Hematology-Oncology | Grosse Pointe Woods, MI | 912 | $65K |
| 2 | Anna Litvak | Hematology-Oncology | Livingston, NJ | 21 | $62K |
| 3 | Sue Tobin | Hematology-Oncology | Saginaw, MI | 731 | $58K |
| 4 | Hikaru Nakajima | Medical Oncology | East Stroudsburg, PA | 1,307 | $43K |
| 5 | Caroline Rivera Olmo | Hematology-Oncology | Barceloneta, PR | 22 | $39K |
| 6 | Monica Santiago Casiano | Hematology-Oncology | Yauco, Puerto Rico, PR | 22 | $37K |
| 7 | Katrina Simmons | Nurse Practitioner | Lowell, MA | 886 | $35K |
| 8 | Anita Ravipati | Hematology-Oncology | Amarillo, TX | 1,351 | $35K |
| 9 | Kit Lu | Hematology-Oncology | Harrisburg, PA | 957 | $35K |
| 10 | Shanti Thomas | Medical Oncology | Brownstown Twp, MI | 481 | $35K |
| 11 | Sowjanya Reganti | Hematology-Oncology | Reno, NV | 1,050 | $34K |
| 12 | Amy Vander Woude | Hematology-Oncology | Grand Rapids, MI | 573 | $32K |
| 13 | Rubina Qamar | Medical Oncology | Milwaukee, WI | 955 | $32K |
| 14 | Savitha Balaraman | Medical Oncology | Madison Heights, MI | 359 | $31K |
| 15 | Ellen Szwed | Hematology-Oncology | Fort Wayne, IN | 907 | $30K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 444 | Cladribine (Mavenclad) | $17.5M | 228 |
| 445 | Enalapril Maleate (Enalapril Maleate) | $17.5M | 673,317 |
| 446 | Vismodegib (Erivedge) | $17.4M | 1,317 |
| 447 | Anastrozole (Anastrozole) | $17.4M | 626,025 |
| 448 | Naproxen (Naproxen) | $17.4M | 903,928 |
| 449 | Vedolizumab (Entyvio) | $17.4M | 2,034 |
| 450 | Abatacept/Maltose (Orencia) | $17.2M | 3,809 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology